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mean fall-related hospital reimbursement of $14,769. LTCF costs
were estimated from RUG classiﬁcations and associated payment
rates. Total reimbursement per resident per year (PRPY) was
calculated as the sum of annualized LTCF and hospital reimburse-
ment. Fall-related costswere estimated as the difference in changes
in reimbursement between groups from pre- to post-periods.
RESULTS: The matched sample included 1130 fallers and 1130
non-fallers. Fallers had substantially more fractures and hospital-
izations in the post-period than non-fallers. The sum of LTCF and
hospital costs increased $4722 PRPY for fallers from pre- to
post-periods; non-fallers’ costs decreased by $1,537 PRPY. The
difference in changes—$6,259 (95% CI = $2,034 to $10,484)
PRPY—represents fall-related costs. About 60% of the difference
was attributable to higher hospitalization costs for fallers. In,
addition fallers weremore likely to be discharged to hospitals or to
die. CONCLUSION: Falls in LTCFs result in substantial costs,
primarily due to higher rates of fractures and hospitalizations.
OSTEOPOROSIS—Health Care Use & Policy Studies
POS12
USE OF OSTEOPOROSIS MEDICATIONS FOLLOWING A
FRACTURE
Herman EO, Carroll NV
Virginia Commonwealth University, Richmond,VA, USA
OBJECTIVES: To estimate the proportion of patients who
receive pharmacologic treatment for osteoporosis following an
osteoporotic fracture and to identify factors that determine
which patients receive treatment. METHODS: Data were taken
from the Medical Expenditures Panel Survey (MEPS) for 2001–
2003. Women who reported a wrist, vertebral, or hip fracture
after the age of 50 years were identiﬁed. Prescription data were
assessed for these subjects and two groups were identiﬁed: those
who received pharmacologic treatment following a fracture and
those who did not. Using Andersen’s Behavioral Model of Health
Services Utilization, two categories of variables were examined
to determine factors related to treatment: characteristics of the
health delivery system and characteristics of the population at
risk. RESULTS: The ﬁnal sample consisted of 129 subjects. This
represented an estimated 1,238,086 women with a history of
osteoporotic fracture during 2001 to 2003 in the civilian, female,
non-institutionalized U.S. population. Of these, 38% received
treatment. Those treated were most likely to receive either
hormone therapy or bisphosphonates. The only variable that was
signiﬁcantly different (p < 0.05) between those treated and not
treated was type of insurance coverage; patients covered by a
private HMO were more likely to receive pharmacologic treat-
ment. CONCLUSION: Most women do not receive pharmaco-
logic treatment for osteoporosis following a fracture. Substantial
efforts should be made to close the gap between guideline rec-
ommendations and clinical practice. We were unable to identify
variables other than insurance coverage that were related to
treatment.
OSTEOPOROSIS—Methods and Concepts
POS13
IMPACT OFTHE ALLOWABLE GAP ON PERSISTENCE INTHE
BISPHOSPHONATE MARKET
Henderson SC1,Von Allmen H1,Weiss TW2
1IMS Health, Blue Bell, PA, USA, 2Merck & Co., Inc,West Point, PA,
USA
OBJECTIVES: Determination of medication persistence, using
administrative pharmacy data, relies on the pharmacist-reported
days supply and an allowable gap between prescriptions. This
concept is used consistently in secondary research, but there are no
standards on the appropriate gap to allow between the run-out of
the days supply of one prescription and the dispensed date of the
patient’s subsequent prescription. The purpose of this research is
to evaluate the impact of varying the allowable gapwhen assessing
persistence in a market with variable dosing frequencies.
METHODS: The osteoporosis market includes competing bis-
phosphonate products with different dosing regimens—weekly or
monthly doses.We assessed the impact of expanding the allowable
gap on persistence and evaluated the impact of allowing different
gaps for each product because differences in dosing frequencies
may impact patients’ reﬁll patterns. Finally, we examined the reﬁll
patterns of patients on each product and the potential impact of
those patterns on the determination of persistence. Cox propor-
tional hazards models, adjusted for patient characteristics, were
used to compare persistence between products. We used the IMS
Longitudinal Prescription (LRx) database, consisting of anony-
mized patient retail prescription records in the U.S. The study
cohort included 165,955 women aged 50 years or older who
initiated therapy between September and November 2005.
RESULTS:As the allowable gap increased, the average persistence
of newly treated bisphosphonate patients also increased (112 days
using 30-day gap, 125 days using 45-day gap), but relative differ-
ences between products were similar, with monthly patients less
persistent than weekly (HR = 1.09 95%CI = (1.08,1.10) using
30-day gap; HR = 1.05 95%CI = (1.03,1.06) using 45-day gap).
When the gap was allowed to differ across products (45-day gap
for monthly vs. 30-day gap for weekly), a different relationship
between products was found (HR = 0.97 95%CI = (0.96,0.98))
CONCLUSION: It is important to consider the allowable gap, in
relation to dosing frequencies, when interpreting results from
persistence measures.
OSTEOPOROSIS—Patient Reported Outcomes
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COMPARISON OF SF-6D AND EQ-5D UTILITIES IN
OSTEOPOROTIC HIP FRACTURE PATIENTS
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OBJECTIVES: To compare SF-6D and EQ-5D in both, absolute
values and sensitivity to change over time, in osteoporotic hip
fracture patients in Poland. METHODS: Data were extracted
from prospective study on outcomes of osteoporotic hip fractures
in Poland (PolHipQol study). Eligible patients had to be 60 years
or more, have low energy femoral neck fracture or pertrochant-
eric fracture of the femur, absence of severe cognitive dysfunction
(measured by Hodkinson’s Abbreviated Mental Test Score) and
both SF-36 and EQ-5D post fracture measurements avaiable.
SF-36 scores were translated into SF-6D utilities using the algo-
rithm developed by Brazier et al. The EQ-5D utilities were based
on the European VAS value set. The correlations between pref-
erence measures were assessed using Spearman’s rank correlation
coefﬁcient. Sensitivity to change over one year was evaluated
with the standardized response mean (SRM). RESULTS: Post
fracture data of 65 patients (mean age 77.8; 54 women) and one
year follow-up data of 51 patients were avaiable (9 patients were
ceased and 5 lost to follow-up). Mean SF-6D utility decreased
from 0.65 (SD 0.13) before fracture (recall method) to 0.49
(0.10) after fracture, and then increased to 0.55 (0.12) at the ﬁnal
follow-up. Mean EQ-5D utility decreased from 0.73 (0.22)
before fracture to 0.24 (0.17) after fracture, and then increased
to 0.47 (0.23) at the ﬁnal follow-up. SF-6D and EQ-5D utilities
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correlated strongly: 0.75 (p < 0.001). The responsiveness was
moderate for SF-6D (SRM = 0.40) and high for EQ-5D
(SRM = 0.83). CONCLUSION: Both SF-6D and EQ-5D cap-
tured worsening and improvements in health over time.
However, the use of EQ-5D resulted in larger utility losses and
gains and in consequence may result in lower cost-utility ratios.
The study showed high responsiveness for EQ-5D and moderate
for SF-6D, indicating that EQ-5D is more suitable for use as
utility measure in clinical trials in elderly hip fracture patients.
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ALLERGY/ASTHMA—Clinical Outcomes Studies
PAA1
SUB-ACUTE LACK OF ASTHMA CONTROL AND
SUBSEQUENT ACUTE ASTHMA EXACERBATIONS: EVIDENCE
FROM MANAGED CARE DATA
Klingman D1, Gutierrez B2, Burudpakdee C1,Wagner S2
1IMS Health, Falls Church,VA, USA, 2AstraZeneca,Wilmington, DE,
USA
OBJECTIVES: To determine whether sub-acute lack of asthma
control (SALAC), independent of current exacerbations, is asso-
ciated with subsequent acute asthma exacerbations. METHODS:
Patients who were aged 12 years as of 2001, continuously
enrolled throughout 2001–2004, and had 1 claims for asthma
(ICD-9-CM code 493.x), no claims for COPD or cystic ﬁbrosis,
and 1 prescriptions for an asthma medication anytime during
2001–2004 were identiﬁed using administrative claims data from
PharMetrics/IMS Health. SALAC was deﬁned as >4 physician
visits for asthma per year (or 2 per quarter) or >5 SABA
prescriptions per year. The impact of asthma control category
during 2001 (exacerbation only, SALAC only, both exacerbation
and SALAC, or neither exacerbation nor SALAC) on having 1
acute asthma exacerbations (hospital admissions, ED visits, or
short-term courses of oral corticosteroid therapy within 7 days of
a physician ofﬁce visit) anytime during 2002–2004 was assessed
using logistic regression. Covariates included gender, age, insur-
ance type, and region. RESULTS: Among 11,779 asthma patients
in 2001, 8% experienced an exacerbation only (EO), 26% expe-
rienced SALAC only (SO), 12% had both an exacerbation and
SALAC (Both), and 54% had neither an exacerbation nor
SALAC (Neither). The 2002–2004 exacerbation rate was higher
in the Both group vs. the EO group (61.8% vs. 55.0%) and in the
SO group vs. the Neither group (37.3% vs. 31.9%). Controlling
for the covariates and compared with the Neither group, the
Both group had a larger impact on the odds of an exacerbation
in 2002–2004 than did the EO group (3.394 [95% CI: 3.009,
3.827] vs. 2.503 [2.176, 2.879], and the SO group had a signiﬁ-
cant and positive effect (1.277 [1.166, 1.399]). CONCLUSION:
SALAC identiﬁes an additional 26% of asthma patients who
have a higher likelihood of a subsequent exacerbation in addition
to the 20% who experienced an exacerbation in 2001.
PAA2
PREVALENCE OF UNCONTROLLED SEVERE PERSISTENT
ASTHMA PATIENTS IN PNEUMOLOGY AND ALLERGY
HOSPITAL UNITS IN SPAIN
Lahoz R1, Picado C2, Plaza V3, Quirce S4, Nadal T5, Casafont J1
1Novartis Pharmaceuticals, Barcelona, Spain, 2Hospital Clínic i
Provincial, Barcelona, Spain, 3Hospital de la Santa Creu i Sant Pau,
Barcelona, Spain, 4Hospital La Paz, Madrid, Spain, 5Trial Form Support,
Barcelona, Spain
OBJECTIVES: Severe persistent asthma is not always adequately
controlled and its prevalence is unknown among pneumology
and allergy hospital units. The aim of this study is to determine
uncontrolled severe persistent asthma prevalence among asth-
matic patients attended in hospital units, to describe their clinical
characteristics and to determine the prevalence of sensibility to
common aeroallergens. METHODS: Cross-sectional epidemio-
logic study conducted in 201 hospital pneumology and allergol-
ogy units in Spain. Asthmatic patients attending these services (in
and out-patients) during a 6-month period were registered.
Demographic data, clinical characteristics, skin-prick test, total
serum IgE, asthma control test (ACQ) and quality of life (AQLQ)
assessments were collected among a sample of asthmatics
patients. RESULTS: A total of 1,423 (3.9% [CI 95%: 3.7–
4.1%]) out of 36,649 asthma patients attending hospital units,
had uncontrolled severe disease, data from 330 was collected.
They showed a poor asthma control (a mean (SD) ACQ score
4.17 [0.96]). 55.9% of the sample had a positive skin-prick test
to common aeroallergens and 53.6% showed high levels of total
serum IgE. The percentage agreement between control assess-
ment by the investigator and by GINA guidelines was moderate
(65.3%, Kappa = 0.365), this discrepancy is basically explained
by an overestimation of control by specialists. CONCLUSION:
1) Uncontrolled severe persistent asthma shows a limited preva-
lence among hospital asthma patients in Spain; 2) The level of the
asthma control is overestimated by physicians; and 3) A half of
the sample fulﬁlled criteria of the allergic disease.
ALLERGY/ASTHMA—Cost Studies
PAA3
A BUDGET IMPACT MODEL FOR DETERMININGTHE COSTS
OF INTRODUCING A NEW EXTRAFINE COMBINATION
(BECLOMETHASONE/FORMOTEROL) FORTHETREATMENT
OF MODERATETO SEVERE PERSISTENT ASTHMA IN SPAIN
Darba J1, Restovic G2
1Universitat de Barcelona, Barcelona, Spain, 2BCN Health Economics
& Outcomes Research, Barcelona, Spain
OBJECTIVES: A budget impact model was developed to esti-
mate the economic impact of introducing beclomethasone/
formoterol extraﬁne for the treatment of moderate to severe
persistent asthma in Spain. METHODS: The analytic model is
based on data from disease prevalence, population growth, drug
consumption, ex-factory prices and market shares forecasting
for Spain. It takes the perspective of the Spanish National Phar-
maceutical budget and time horizon considered is 5 years.
Annual discount rate was set at 5%. Drugs considered in the
study were ﬂuticasone/salmeterol, budesonide/formoterol and
beclomethasone/formoterol extraﬁne. The model estimates the
annual cost to treat patients with moderate to severe persistent
asthma before and after the introduction of beclomethasone/
formoterol extraﬁne in Spain. Annual costs consist of pharma-
cologic treatment costs, laboratory and diagnostic tests costs,
specialist consultation costs and hospitalization costs. All costs
are referred to 2007. RESULTS: It has been estimated that target
population with moderate to severe persistent asthma in Spain
would be around 284,365 in year 2007, arriving at 498,385 in
2012 due to increase in Spanish population and the increase of
asthma prevalence. Total cost for the next 5 years for the treat-
ment of moderate to severe persistent asthma in Spain was
estimated at 1700€ millions before the introduction of
beclomethasone/formoterol extraﬁne and at 1689€ millions after
its introduction. Mean cost per patient was estimated at 642€
before the introduction of beclomethasone/formoterol extraﬁne
and at 637€ after its introduction. CONCLUSION: This budget
impact model estimates that the introduction of beclomethasone/
formoterol extraﬁne for the treatment of moderate to severe
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